Targeting macrophage migration inhibitory factor (MIF): a promising therapy for inflammatory ocular diseases

Inflammatory ocular diseases are characterized by the presence of a persistent inflammatory response which cause tissue injury, decrease visual acuity and in severe cases, blindness. Several cytokines represent a therapeutic opportunity since they are key amplifiers of these pathologies, and thus ne...

Full description

Saved in:
Bibliographic Details
Published inJournal of ophthalmic inflammation and infection Vol. 13; no. 1; p. 37
Main Authors Vázquez, Alicia, González, Marisol I., Reyes, José L.
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 25.08.2023
Springer Nature B.V
SpringerOpen
Subjects
Cornea
Cytokines
Eye diseases
Immune system
Infections
Inflammation
Kinases
Medicine
Medicine & Public Health
MIF
Ocular inflammation
Ocular Neovascularization
Ophthalmology
Proteins
Retina
Review
Rodents
Stem cells
Therapy
Ocular Neovascularization
Therapy
MIF
Cytokines
Ocular inflammation
Online AccessGet full text

Cover

More Information
Summary:Inflammatory ocular diseases are characterized by the presence of a persistent inflammatory response which cause tissue injury, decrease visual acuity and in severe cases, blindness. Several cytokines represent a therapeutic opportunity since they are key amplifiers of these pathologies, and thus neutralizing agents against them have been developed. Amongst others, macrophage migration inhibitory factor (MIF), an early produced inflammatory cytokine, has consistently been found elevated in patients with distinct ocular diseases (inflammatory and autoimmune). Here, we present and discuss evidence showing that preclinical trials using diverse strategies to neutralize MIF resulted in significant attenuation of disease signs and therefore MIF blockage might be a promising therapy for ocular diseases.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1869-5760
1869-5760
DOI:10.1186/s12348-023-00361-2